Abstract: Malignant struma ovarii is a rare disease in gynecology and the optimal treatment regimen for the tumor remains obscure. We present a patient who had malignant struma ovarii with peritoneal implants and pelvic structures and liver metastases shown on posttreatment iodine I-131 single-photon emission tomography (SPECT) and low-dose computed tomography (CT). The roles of I-131 ablation in the management of the disease are reviewed and discussed.
FIGURE 1.
A 49-year-old female patient presented with abdominal distension and an ovarian mass were seen on abdominal sonogram and CT. Total abdominal hysterectomy and bilateral salpingo-oophorectomy and infracolic omentectomy were performed. Pathologic examination revealed malignant struma ovarii with peritoneal studding. She was subsequently treated with thyroidectomy and I-131 ablation. Posttreatment I-131 whole-body scan (left: anterior view, right: posterior view) demonstrated increased activity in the thyroid bed (T), liver (L), abdominal cavity (Ab), and pelvic structures (P).
FIGURE 2.
SPECT/CT study of the abdomen and pelvis (transaxial, left; CT, middle; SPECT, right; fused SPECT/CT) confirms evidence of radioiodine uptake in the mentioned areas. Malignant struma ovarii with distal metastases is uncommon. [1] [2] [3] [4] The most common sites are the contralateral ovary, pelvic structures, bone, brain, liver, and lungs. [2] [3] [4] In addition, metastases can simulate peritoneal seeding of struma ovarii. [5] [6] [7] The modalities of treatment of malignant struma ovarii are still controversial because it is rarely encountered. However, thyroidectomy and I-131 ablation are recommended for advanced disease. 8, 9 DeSimone 9 reviewed a total of 12 patients with the disease and found that I-131 provided an initial complete response in all 4 patients for postoperative treatment and in 7 of 8 patients for recurrent disease. Thus, thyroidectomy and I-131 ablation should be considered in the first priority of management for malignant struma ovarii.
